RPTR-147 is under clinical development by Repertoire Immune Medicines and currently in Phase II for Metastatic Ovarian Cancer. According to GlobalData, Phase II drugs for Metastatic Ovarian Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RPTR-147’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RPTR-147 is under development for the treatment of relapsed/refractory, metastatic malignancies including non-small cell lung cancer, melanoma, clear cell cancer of the kidney, head and neck squamous cell cancer, urothelial cancer, lymphoma, sarcomas and ovarian cancer. Drug candidate comprises the polymer of IL-15 chemically linked to T cells with a reversible cross-linker. It is developed based on Deep primed technology platform.
Repertoire Immune Medicines overview
Repertoire Immune Medicines (Repertoire) is a biotechnology company that discover and develops novel immune therapies to treat cancer, immune disorders and infectious disease. The company is investigating pipeline programs such as PRIME IL-15 (RPTR-147), a non-genetically modified multi-clonal T cell therapeutic candidate targeting solid tumors; PRIME IL-12 (RPTR 168), a multi-targeted T cell (MTC) investigational therapy designed to provide anti-tumor immune response for various cancer indications. It utilizes its proprietary DECODE platform to develop therapies against type 1 diabetes, infectious disease and gastrointestinal cancer. Repertoire uses DEPLOY and DECODE suite of technologies to design and develop immune medicines. The company works in collaboration with academic and clinical institutions to develop drugs in the areas of cancer and autoimmunity. Repertoire is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of RPTR-147’s drug-specific PTSR and LoA scores, buy the report here.